|
|
||||||||||||||
|
|
|||||||||||||||
Therapeutics |
| The first 150 words of the full text of this article appear below. |
Design
Randomised {allocation concealed*}
, blinded (participants and health care providers),* controlled trial with 52 weeks of follow up.
Setting
15 Veterans Affairs medical centres in the US.
Patients
627 outpatients (mean age 49 y, 98% men) who had a diagnosis of alcohol dependence according to the Diagnostic and Statistical Manual of Mental Disorders, 4th ed, criteria; who had not drunk for
5 days; and who had a recent history of drinking to intoxication (
6 drinks for men and
4 drinks for women at least twice during a 1 wk period in the 30 d before screening). Exclusion criteria included previous use of naltrexone and other substance abuse or dependence. Follow up was 90% and 93% at 13 and 52 weeks, respectively.
Intervention
209 patients each were allocated to naltrexone, 50 mg once daily, for 3 months (short term group); naltrexone, 50 mg once daily, for 12 months (long term group);
Jonathan Chick, MA, MPhil, FRCPsych
Royal Edinburgh Hospital, Edinburgh, Scotland, UK
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |